unpopular opinion: most of what gets said here about phase 2 is guesswork
unpopular opinion: most of what gets said here about phase 2 is guesswork. Change my mind, genuinely — I have no stake in being right about this.
The standing caveat, written out properly because it keeps getting compressed into a footnote.
Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.
What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
Where the evidence actually stands, since every thread here assumes a different answer.
Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.
Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
What the glucagon arm is doing, as best anyone can say from public data.
GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.
Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
Kept a log specifically because there is so little published. It is one person and it is not data.
the glucagon component is why the metabolic story reads differently
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.
That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.
the TRIUMPH programme is still running, so anything definitive is premature
not approved anywhere, which is the single most important fact in this board
The injection-site soreness profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
the phase 2 numbers were striking and they were also 48 weeks in a small population
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.
Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
heart rate is the thing people report watching
heart rate is the thing people report watching
Agreed, and the glucagon arm is exactly why the comparison threads do not work.
the escalation is where most of the reported trouble sits
phase 2 data only, and people quote it like it is a label
Correcting my own comment above: that figure was the 36-week interim, not the 48-week endpoint.
Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.
- 1Glucagon receptor agonism is associated with increased energy expenditure…8 comments in this branch · started by u/signe_villalobos
- 2The thing that surprised me was how much of the discussion here is inference…7 comments in this branch · started by u/aa_analysis_andy